|
|
|
||
|
|
||
|
||
| Title: | First-line Treatment of Newly Diagnosed Multiple Myeloma with Combination of Low Dose Thalidomide, Zometa, and Dexamethasone |
|---|---|
|
|
| Phase: | II |
|
|
| Purpose: | To determine effectiveness of combination therapies with thalidomide for patients with newly diagnosed multiple myeloma |
|
|
| Eligibility: |
|
|
|
| Treatment: | Patients receive oral thalidomide at 100 mg per day, IV Zometa® administered every 4 weeks, and oral dexamethasone at 40 mg per day on 4 days out of the week. This continues for 3 out of 4 weeks per month for 6 months. Dose of dexamethasone may be reduced and Biaxin® may be added depending upon patient response |
|
|
| Contact: |
New York SUNY-Downstate Medical Center Dr. Olcay Batuman 718-270-2785 |
|
|
| Please note: the trials indicated do not include the full inclusion or exclusion criteria. For full protocols, please contact the Principal Investigator (PI) listed. |
|
|
|
|
|
|
|